Share This Page
Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC (D. Del. 2023)
✉ Email this page to a colleague
Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC (D. Del. 2023)
Small Molecule Drugs cited in Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC
Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-06-30 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC (D. Del. 2023)
Boehringer Ingelheim v. Anobri (1:23-cv-00715) Patent Litigation Summary, Claims, and Generic Entry Risk Analysis
Executive summary: In Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC, No. 1:23-cv-00715 (D. Del.), Boehringer in gelheim is asserting patent rights against Anobri to block FDA approval and/or launch of a generic or follow-on product tied to Boehringer’s branded asset(s). The case is filed as a Hatch-Waxman-style infringement action, implying an Orange Book listing and a Paragraph IV (or related) challenge by Anobri. The litigation’s near-term risk for Anobri is driven by (i) the asserted patent claims, (ii) whether Boehringer seeks preliminary relief, and (iii) whether the case is early-stage (motion practice and claim construction) versus post-discovery. The competitive impact hinges on the product’s FDA readiness and any settlement that could trigger delayed launch or non-infringing design-arounds.
What this analysis covers: procedural posture, typical claim structure in this case type, litigation timeline checkpoints that determine exclusivity leverage, and the generic launch risk framework based on how Hatch-Waxman litigations move in practice.
What is the case status in Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC (1:23-cv-00715)?
Short answer: The matter is pending in the US District Court for the District of Delaware under civil action number 1:23-cv-00715. The available prompt does not include the docket’s current filing status, last event date, or whether the parties reached a stipulated stay or settlement.
Key posture milestones that typically determine outcomes
The following milestones usually control tempo and settlement value in Hatch-Waxman patent suits:
- Complaint and infringement theories: asserted Orange Book patents and infringement basis tied to the ANDA product.
- Answer and defenses: invalidity, non-infringement, unenforceability.
- Rule 12 and transfer motions: venue, jurisdiction, pleading sufficiency.
- Claim construction (Markman): narrows claim meaning and can pressure settlement.
- Summary judgment: invalidity/non-infringement can end the case early.
- Trial: rare if a license settlement resolves.
- Injunction posture: some cases include motions for preliminary relief.
Actionable reading: if the docket is still in pre-Markman or discovery, settlement is often more likely than after claim construction if the court signals strong claim scope alignment.
Which patents are asserted in Boehringer Ingelheim v. Anobri (1:23-cv-00715)?
Short answer: The asserted patent numbers and claim sets are not included in the provided input.
How to map asserted patents to generic launch risk
In Boehringer/ANDA litigation, the asserted estate usually splits into one or more of the following categories:
- Composition-of-matter (strongest scope, hardest to design around)
- Method-of-use (can be avoided via labeling or carve-outs, depending on statutory trigger)
- Formulation or dosage form (design-arounds possible but may require evidence)
- Manufacturing or process (harder if generic is functionally equivalent)
- Polymorph/crystal form (design-around depends on product selection)
- Combination patents (avoidance may be impossible if ANDA covers same combination)
Actionable reading: the highest blocking value is composition-of-matter and combination claims, particularly if they have late expiry or survive invalidity challenges.
Is this case a Paragraph IV (ANDA) dispute, and what does that imply for the court timeline?
Short answer: The caption and case type strongly indicate a Hatch-Waxman infringement action tied to an ANDA and an Orange Book patent challenge. The specific FDA pathway and Paragraph IV label are not provided in the prompt.
Typical timeline consequences
Where an ANDA Paragraph IV is involved:
- A first-filer generic often has a 180-day exclusivity entitlement subject to forfeiture events (court decision timing and regulatory triggers).
- Litigation outcomes can dictate launch timing through:
- Automatic statutory stays pending litigation outcome (under Hatch-Waxman)
- Settlement-triggered launch dates
- Non-infringement/invalidity judgments that lift blocking patents
Actionable reading: if this is a first-filer dispute, the economic stakes of an early claim construction outcome are high.
What is Boehringer Ingelheim’s legal theory against Anobri in 1:23-cv-00715?
Short answer: Not stated in the prompt.
Common infringement frameworks in Boehringer-style Hatch-Waxman cases
Boehringer’s theory in ANDA litigation typically tracks one or more of:
- Direct infringement of product claims by the ANDA drug as manufactured and sold.
- Induced or contributory infringement where method-of-use claims are asserted.
- Literal infringement versus doctrine-of-equivalents disputes depending on how the ANDA product is designed.
Actionable reading: if Boehringer pleads infringement under multiple theories across different patent families, the probability of settlement increases because narrowing at Markman may not eliminate all theories.
What defenses has Anobri asserted in Boehringer Ingelheim v. Anobri (1:23-cv-00715)?
Short answer: Not included in the provided input.
Defense map that drives outcomes
Common defenses include:
- Non-infringement: ANDA product does not meet claim limitations.
- Invalidity:
- anticipation (single prior art reference)
- obviousness (combination)
- lack of enablement or written description
- Inequitable conduct / unenforceability: less common but high leverage.
- Statutory bars: improper Orange Book listing or failure to comply with listing requirements (rare in merits posture).
Actionable reading: if Anobri’s invalidity case relies on a small number of references, Boehringer may counter with strong distinctions that are decided at Markman or summary judgment.
Has the court entered any interim orders (stay, preliminary injunction, or claim construction) in 1:23-cv-00715?
Short answer: The prompt does not include docket orders, dates, or substance.
How interim orders affect settlement and generic entry
In practice, the market impact comes from:
- Scheduling order (discovery pace, Markman date)
- Claim construction rulings (scope tightening or expansion)
- Stays (often settlement-related)
- Preliminary injunction motions (rare for Hatch-Waxman but value-setting if granted)
Actionable reading: if claim construction has already occurred, the decision often anchors final settlement ranges.
Does this case involve an Orange Book-listed patent that triggers a statutory stay?
Short answer: The prompt does not identify the specific Orange Book listings.
How Orange Book status drives exclusivity leverage
If the asserted patents are Orange Book-listed and properly tied to the NDA:
- filing an ANDA AND Paragraph IV notice triggers a statutory 30-month stay of FDA approval pending litigation outcome
- the stay lifts if the patentee loses or patents are held invalid/not infringed
Actionable reading: if Boehringer asserts multiple patents across different expiry dates, court or settlement outcomes can still leave one later-expiring patent to block launch.
What are the typical settlement terms in Boehringer Ingelheim patent litigations like 1:23-cv-00715?
Short answer: Not provided.
Deal structures that matter for launch timing
When Boehringer resolves Hatch-Waxman suits by settlement, terms commonly include:
- Agreed launch date delayed until a patent expiry or a stipulated “carve-out” date
- License for one or more patents with ongoing royalties
- Non-cash design-around commitments (label or formulation changes)
- Mutual releases with specified exclusions
Actionable reading: where the portfolio includes method-of-use and formulation patents, settlements can be structured to allow market entry under a changed labeling or composition, while still compensating for residual exclusivity.
How strong is Boehringer Ingelheim’s patent estate likely to be in 1:23-cv-00715?
Short answer: Strength cannot be scored from the provided input because the asserted patent numbers, claim scope, and expiration dates are not included.
Strength scoring framework used for investment and licensing decisions
A practical assessment uses:
- Remaining term of each asserted patent
- Claim breadth after typical claim construction outcomes
- Prior art quality and whether invalidity hinges on a single reference
- Litigation history of the patent family in other forums
- Commercial reliance (if the branded product drives major revenue, courts often see aggressive enforcement)
Actionable reading: the strongest estate effect comes from patents near full term remaining and those with fewer design-around routes.
What generic entry risks exist for Anobri if Boehringer wins in 1:23-cv-00715?
Short answer: Not determinable without knowing the product, patent list, and timeline status.
Risk matrix
If Boehringer prevails on all asserted claims:
- FDA approval is delayed until appellate timelines end or statutory stays expire
- Anobri’s launch may be blocked until patent expiry (or until the last asserted patent is resolved)
- Settlement becomes more likely but at a higher cost to Anobri
If Boehringer prevails on some asserted patents:
- launch may still be possible if Anobri’s design-around avoids the remaining blocking claims
- otherwise, launch is delayed to the remaining patent’s expiry
If Anobri prevails:
- FDA approval can proceed sooner
- Anobri’s 180-day exclusivity status becomes pivotal
How does this litigation compare with other Boehringer Ingelheim vs. generic actions?
Short answer: Comparison requires asserted patents and product identity, which are not included in the prompt.
Benchmark patterns
Across large pharma Hatch-Waxman portfolios, common patterns include:
- parallel litigation against multiple ANDA filers
- settlements that map to patent-by-patent expiry
- early claim construction frequently used as settlement leverage
Actionable reading: if similar Boehringer cases in the same therapeutic area have settled, the market expects comparable launch dates and design-around pathways.
What is the commercial exposure tied to 1:23-cv-00715?
Short answer: The prompt does not identify the drug, NDA, or projected generic revenue.
Exposure drivers to quantify once product identity is known
- peak and current branded sales in US
- list price and reimbursement category
- anticipated ANDA launch month and exclusivity status
- likelihood and cost of design-around development
- probability of settlement and stipulation terms affecting time-to-market
Key Takeaways
- Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC, No. 1:23-cv-00715, is pending in the District of Delaware and is structured like a Hatch-Waxman patent infringement dispute.
- The litigation’s decisive drivers are not present in the provided input: asserted patent identifiers, claim categories, and current docket posture (Markman, summary judgment, or settlement).
- Generic entry risk for Anobri is primarily governed by whether Boehringer can preserve at least one Orange Book-listed blocking patent through claim construction and dispositive rulings, and by whether any settlement establishes a stipulated launch date.
- Economic impact depends on the FDA pathway (likely ANDA), statutory stay status, and any first-filer/180-day exclusivity implications tied to the Paragraph IV posture.
FAQs
- What happens to FDA approval timing when Boehringer wins on some but not all asserted patents in an ANDA case?
- How do claim construction rulings typically change settlement leverage in Hatch-Waxman litigations?
- When do design-around attempts succeed in stopping infringement allegations for formulation or method-of-use patents?
- What forfeiture events can eliminate 180-day exclusivity in multi-filer ANDA scenarios?
- How do appellate timelines affect practical launch timing even after a district court decision?
References
- US District Court for the District of Delaware, civil action No. 1:23-cv-00715 (Boehringer Ingelheim Pharmaceuticals Inc. v. Anobri Pharmaceuticals US, LLC).
More… ↓
